Formulation Development

1. Liquid Injectables

  • Carbetocin injection 100 micrograms/mL in glass vials
  • Brexanolone injection, 100 mg brexanolone in 20 mL (5 mg/mL) aq. Solution
  • Sugammadex injection 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) in a single-dose vial
  • Ganirelix Acetate injection in 1 mL prefilled glass syringes containing 250 mcg/0.5 mL as aqueous solution


2. Lyophilized Injections

  • Cetrorelix Acetate for injection: 0.25 mg cetrorelix/ vial
  • Micafungin for injection, 50 mg micafungin (equivalent to 50.86 mg micafungin sodium) or 100 mg micafungin (equivalent to 101.73 mg micafungin sodium)
  • Anidulafungin for injection, 50mg & 100 mg/vial
  • Degarelix for injection 120 mg of degarelix (equivalent to the median value of 126 mg degarelix acetate) and 80mg (equivalent to the median value of 84 mg degarelix acetate).


3. Solid Orals tablets/ capsules

  • Sarecycline film coated tablets, 60 mg, 100 mg, and 150 mg
  • Saroglitazar Calcium tablets 2mg and 4mg
  • Everolimus tablet 0.25mg


4. Complex Generics (Oral Peptides)

  • Semaglutide Tablets 3 mg, 7 mg, 14 mg
  • Linaclotide Hard Gelatin Capsule, 72 mcg, 145 mcg and 290 mcg
  • Plecanatide tablet 3mg

5. Complex Novel Injectables

  • Triptorelin Acetate Microsphere injectable suspension 3.75mg per vial every 4week, 11.25 mg per vial every 12 weeks; 22.5 mg per vial for every 24 weeks
  • Leuprolide Acetate for depot suspension (lyophilized microspheres), 3.75 mg (1M), 7.5 mg (1M), 22.5 mg (3M), 30 mg (4M), and 45 mg (6M) per vial for injection